WO1995020395A1 - Medicament contre des maladies atopiques - Google Patents
Medicament contre des maladies atopiques Download PDFInfo
- Publication number
- WO1995020395A1 WO1995020395A1 PCT/JP1994/000124 JP9400124W WO9520395A1 WO 1995020395 A1 WO1995020395 A1 WO 1995020395A1 JP 9400124 W JP9400124 W JP 9400124W WO 9520395 A1 WO9520395 A1 WO 9520395A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- atopic
- interferon
- administration
- atopic disease
- diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Definitions
- the present invention relates to a novel therapeutic agent for an atopic disease.
- Atopic disease is a general term for allergic diseases that develop when an individual with a familial predisposition to sensitization to an exogenous allergen is exposed to the allergen.
- Patients with a predisposition to the disease are susceptible to a high degree of hypersensitivity to dietary and inhalable antigens, as well as external invasion such as heat, cold, It is characterized by abnormalities in autonomic nervous system, endocrine function, and immunity due to internal stress such as tension. Specifically, it refers to diseases such as atopic dermatitis, exogenous bronchial asthma, urticaria, allergic rhinitis and allergic gastroenteritis.
- antihistamines are used as symptomatic therapies for atopic diseases.
- the drug is considered a clinical problem because it cannot be effective without long-term administration and has local and systemic side effects.
- Useful drugs that can replace or assist the drug, and drugs that can treat the cause, are expected to emerge.
- immunomodulators for immunological abnormalities revamizol, Use of run-factors, tymo-pentines *, pen-types, and cyclosporins have also been attempted.
- interferon and interferon ⁇ which are known to have strong immunomodulatory effects, strongly suppress IgE production by lymphocytes (Pene J. et a 1, Proc. Nat. Acad. Sci. (USA), 1988; 85, 6880-4) Inhibition of production of interferon 7 in locally infiltrated lymphocytes from atopic dermatitis and asthma. (J. Immunol., 1979; 123, 1788-94), suggests that interferon 7 suppresses the enhancement of helper T2 cells (Gajewski TF et al., J. Immunol., 1988; 140, 4245).
- An object of the present invention is to overcome such disadvantages of the conventional drugs and to provide a more effective new therapeutic drug for atopic diseases.
- the present invention relates to a therapeutic agent for atopic diseases, which contains interfuron as an active ingredient.
- the interferon used in the present invention may be any of natural types, those produced by chemical synthesis, those produced by gene recombination technology, and polypeptides having their active partial structures. May be used.
- native interferon ⁇ produced by human diploid fibroblasts is particularly preferably used.
- Natural interferon 8 is usually an interferon-producing cell cultured on a surface such as glass or plastic, or on one surface of DEAE-dextran-based microcarriers.
- Induction treatment with synthetic double-stranded RN ⁇ , such as ⁇ I: C, followed by hyper-induction treatment (eg, metabolic inhibition by combination of orifice heximide and actinomycin D or ultraviolet irradiation) ), And then cultured in a culture solution for 20 to 48 hours to produce it in this culture solution and obtain it as a production solution containing human interferon; Is done.
- the interferon in the production solution obtained in this manner is generally at a low concentration, and this production solution contains many contaminants derived from cells or additives in addition to interfuron; 5. Since it is contained, it is necessary to concentrate and purify interferon for medical use.
- the method for concentrating and purifying interferon S is not particularly limited, but is preferably a method based on mouth chromatography using an insoluble carrier to which a true dye is bound and a metal-chelate group-bound carrier. That is, after contacting the crude interferon-containing solution with an insoluble carrier to which blue dye has been bound, the interferon is recovered as a solution using an eluate, and then the interferon is recovered. This method involves contacting a solution with a chelating group-binding carrier in which a metal such as zinc is chelated, collecting the solution using an eluate, and obtaining concentrated and purified perfluorocarbon. .
- the interferon / S of the present invention can be used for various types of atopic dermatitis, such as atopic dermatitis, atopic asthma, urticaria, allergic rhinitis, allergic gastroenteritis, etc. It is effective as a remedy for a group of diseases having symptoms, especially for atopic dermatitis and atopic asthma.
- the interfuron of the present invention when used as a therapeutic agent for atopic diseases, it may be used as it is or as a pharmaceutical composition mixed with a known pharmacologically acceptable carrier, excipient, or the like. It can be administered orally or parenterally.
- the therapeutic agent for atopic diseases of the present invention includes More stabilizers can be added. Examples of such a stabilizer include human serum albumin, a polyol disclosed in JP-A-58-92619, and a polyol disclosed in JP-A-58-92621. Organic acid buffers and the like can be exemplified.
- various dosage forms are used, including injections, oral preparations, nasal preparations, pulmonary preparations, gastrointestinal mucosal preparations, ointments, and liniments.
- the dosage is appropriately determined depending on the administration subject, administration method, symptoms, and the like, but is generally 100,000 to 100,000 units per day for systemic administration, preferably 500,000 to 70,000 units. 0,000 units Z days, topical administration: 1/1/10 to 11,000.
- Table 1 shows the numbers of leukocytes and eosinophils before and after administration. The eosinophil count before administration was low, but remained low during administration.
- Interfuron yS significantly improves the skin symptoms of atopic dermatitis, significantly reduces the number of eosinophils in blood, which is a factor in the production of allergic reactions, and is fast-acting and durable. Yes, it is useful as a therapeutic drug for atopic diseases.
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP20396892A JP3269125B2 (ja) | 1994-01-28 | 1992-07-30 | アトピー性皮膚炎治療薬 |
KR1019950704026A KR100278351B1 (ko) | 1994-01-28 | 1994-01-28 | 아토피성질환 치료약 |
EP94905228A EP0694307B1 (en) | 1994-01-28 | 1994-01-28 | Atopic disease remedy |
DE69427970T DE69427970T2 (de) | 1994-01-28 | 1994-01-28 | Medikament gegen atopische krankheiten |
PCT/JP1994/000124 WO1995020395A1 (fr) | 1994-01-28 | 1994-01-28 | Medicament contre des maladies atopiques |
US08/525,755 US5709853A (en) | 1994-01-28 | 1994-01-28 | Method of treatment of atopic disease |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP1994/000124 WO1995020395A1 (fr) | 1994-01-28 | 1994-01-28 | Medicament contre des maladies atopiques |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1995020395A1 true WO1995020395A1 (fr) | 1995-08-03 |
Family
ID=14098153
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1994/000124 WO1995020395A1 (fr) | 1994-01-28 | 1994-01-28 | Medicament contre des maladies atopiques |
Country Status (6)
Country | Link |
---|---|
US (1) | US5709853A (ja) |
EP (1) | EP0694307B1 (ja) |
JP (1) | JP3269125B2 (ja) |
KR (1) | KR100278351B1 (ja) |
DE (1) | DE69427970T2 (ja) |
WO (1) | WO1995020395A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5952296A (en) * | 1993-07-27 | 1999-09-14 | Bigazzi; Mario | Method of using relaxin as therapeutic or preventing agent |
Families Citing this family (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3269125B2 (ja) * | 1994-01-28 | 2002-03-25 | 東レ株式会社 | アトピー性皮膚炎治療薬 |
US6121247A (en) * | 1996-03-29 | 2000-09-19 | The Johns Hopkins University | Therapy for allergic diseases |
JP3845915B2 (ja) * | 1996-10-31 | 2006-11-15 | 東レ株式会社 | ネコのアトピー性皮膚炎治療剤および治療方法 |
US8914114B2 (en) | 2000-05-23 | 2014-12-16 | The Feinstein Institute For Medical Research | Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation |
US6610713B2 (en) * | 2000-05-23 | 2003-08-26 | North Shore - Long Island Jewish Research Institute | Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation |
US20040048795A1 (en) * | 2002-02-26 | 2004-03-11 | North Shore-Long Island Jewish Research Institute | Inhibition of inflammatory cytokine production by stimulation of brain muscarinic receptors |
US10912712B2 (en) | 2004-03-25 | 2021-02-09 | The Feinstein Institutes For Medical Research | Treatment of bleeding by non-invasive stimulation |
JP2007530586A (ja) * | 2004-03-25 | 2007-11-01 | ザ ファインスタイン インスティテュート フォー メディカル リサーチ | 神経性止血法 |
US11207518B2 (en) | 2004-12-27 | 2021-12-28 | The Feinstein Institutes For Medical Research | Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway |
EP2298410B1 (en) | 2004-12-27 | 2013-10-09 | The Feinstein Institute for Medical Research | Treating inflammatory disorders by electrical vagus nerve stimulation |
CA2676119C (en) | 2007-01-29 | 2021-01-19 | Simon Fraser University | Transvascular nerve stimulation apparatus and methods |
EP2129352B1 (en) * | 2007-03-13 | 2016-03-09 | The Feinstein Institute for Medical Research | Treatment of inflammation by non-invasive stimulation |
US8391970B2 (en) | 2007-08-27 | 2013-03-05 | The Feinstein Institute For Medical Research | Devices and methods for inhibiting granulocyte activation by neural stimulation |
US9662490B2 (en) | 2008-03-31 | 2017-05-30 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug |
WO2009146030A1 (en) * | 2008-03-31 | 2009-12-03 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation of t-cell activity |
US20090275997A1 (en) * | 2008-05-01 | 2009-11-05 | Michael Allen Faltys | Vagus nerve stimulation electrodes and methods of use |
EP2355893B1 (en) * | 2008-11-18 | 2013-12-25 | Setpoint Medical Corporation | Devices for optimizing electrode placement for anti-inflamatory stimulation |
TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
US9211410B2 (en) | 2009-05-01 | 2015-12-15 | Setpoint Medical Corporation | Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
US8996116B2 (en) | 2009-10-30 | 2015-03-31 | Setpoint Medical Corporation | Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction |
AU2010258792B2 (en) | 2009-06-09 | 2015-07-02 | Setpoint Medical Corporation | Nerve cuff with pocket for leadless stimulator |
US9833621B2 (en) | 2011-09-23 | 2017-12-05 | Setpoint Medical Corporation | Modulation of sirtuins by vagus nerve stimulation |
US11051744B2 (en) | 2009-11-17 | 2021-07-06 | Setpoint Medical Corporation | Closed-loop vagus nerve stimulation |
AU2010336337B2 (en) | 2009-12-23 | 2016-02-04 | Setpoint Medical Corporation | Neural stimulation devices and systems for treatment of chronic inflammation |
WO2012154865A2 (en) | 2011-05-09 | 2012-11-15 | Setpoint Medical Corporation | Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
DE102011052816A1 (de) * | 2011-08-18 | 2013-02-21 | Tigo Gmbh | Verwendung von Interferon-beta zur Behandlung von Alopecia areata |
CN107126622A (zh) | 2012-03-05 | 2017-09-05 | 西蒙·弗雷瑟大学 | 神经刺激系统 |
US9572983B2 (en) | 2012-03-26 | 2017-02-21 | Setpoint Medical Corporation | Devices and methods for modulation of bone erosion |
EP2863987B1 (en) | 2012-06-21 | 2023-08-02 | Lungpacer Medical Inc. | Transvascular diaphragm pacing systems |
US9242088B2 (en) | 2013-11-22 | 2016-01-26 | Simon Fraser University | Apparatus and methods for assisted breathing by transvascular nerve stimulation |
EP3096835B1 (en) | 2014-01-21 | 2019-08-07 | Lungpacer Medical Inc. | Systems for optimization of multi-electrode nerve pacing |
US11311725B2 (en) | 2014-10-24 | 2022-04-26 | Setpoint Medical Corporation | Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation |
US11406833B2 (en) | 2015-02-03 | 2022-08-09 | Setpoint Medical Corporation | Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator |
US10596367B2 (en) | 2016-01-13 | 2020-03-24 | Setpoint Medical Corporation | Systems and methods for establishing a nerve block |
CN108882885A (zh) | 2016-01-20 | 2018-11-23 | 赛博恩特医疗器械公司 | 迷走神经刺激的控制 |
WO2017127758A1 (en) | 2016-01-20 | 2017-07-27 | Setpoint Medical Corporation | Implantable microstimulators and inductive charging systems |
US11471681B2 (en) | 2016-01-20 | 2022-10-18 | Setpoint Medical Corporation | Batteryless implantable microstimulators |
US10583304B2 (en) | 2016-01-25 | 2020-03-10 | Setpoint Medical Corporation | Implantable neurostimulator having power control and thermal regulation and methods of use |
US10293164B2 (en) | 2017-05-26 | 2019-05-21 | Lungpacer Medical Inc. | Apparatus and methods for assisted breathing by transvascular nerve stimulation |
US20190001126A1 (en) | 2017-06-30 | 2019-01-03 | Lungpacer Medical Inc. | Devices and methods for prevention, moderation, and/or treatment of cognitive injury |
US10195429B1 (en) | 2017-08-02 | 2019-02-05 | Lungpacer Medical Inc. | Systems and methods for intravascular catheter positioning and/or nerve stimulation |
US10940308B2 (en) | 2017-08-04 | 2021-03-09 | Lungpacer Medical Inc. | Systems and methods for trans-esophageal sympathetic ganglion recruitment |
US11173307B2 (en) | 2017-08-14 | 2021-11-16 | Setpoint Medical Corporation | Vagus nerve stimulation pre-screening test |
US11260229B2 (en) | 2018-09-25 | 2022-03-01 | The Feinstein Institutes For Medical Research | Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation |
EP3877043A4 (en) | 2018-11-08 | 2022-08-24 | Lungpacer Medical Inc. | STIMULATION SYSTEM AND ASSOCIATED USER INTERFACES |
WO2020232333A1 (en) | 2019-05-16 | 2020-11-19 | Lungpacer Medical Inc. | Systems and methods for sensing and stimulation |
US11771900B2 (en) | 2019-06-12 | 2023-10-03 | Lungpacer Medical Inc. | Circuitry for medical stimulation systems |
US11938324B2 (en) | 2020-05-21 | 2024-03-26 | The Feinstein Institutes For Medical Research | Systems and methods for vagus nerve stimulation |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63501013A (ja) * | 1985-09-09 | 1988-04-14 | バイオジェン インコーポレイテッド | アレルギ−の処置方法 |
JPH05501716A (ja) * | 1989-12-01 | 1993-04-02 | チルドレンズ・メデイカル・センター・コーポレーシヨン | γインターフエロンによるアトピー性疾患の処置 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3269125B2 (ja) * | 1994-01-28 | 2002-03-25 | 東レ株式会社 | アトピー性皮膚炎治療薬 |
-
1992
- 1992-07-30 JP JP20396892A patent/JP3269125B2/ja not_active Expired - Fee Related
-
1994
- 1994-01-28 DE DE69427970T patent/DE69427970T2/de not_active Expired - Fee Related
- 1994-01-28 KR KR1019950704026A patent/KR100278351B1/ko not_active IP Right Cessation
- 1994-01-28 EP EP94905228A patent/EP0694307B1/en not_active Expired - Lifetime
- 1994-01-28 US US08/525,755 patent/US5709853A/en not_active Expired - Lifetime
- 1994-01-28 WO PCT/JP1994/000124 patent/WO1995020395A1/ja active IP Right Grant
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63501013A (ja) * | 1985-09-09 | 1988-04-14 | バイオジェン インコーポレイテッド | アレルギ−の処置方法 |
JPH05501716A (ja) * | 1989-12-01 | 1993-04-02 | チルドレンズ・メデイカル・センター・コーポレーシヨン | γインターフエロンによるアトピー性疾患の処置 |
Non-Patent Citations (1)
Title |
---|
See also references of EP0694307A4 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5952296A (en) * | 1993-07-27 | 1999-09-14 | Bigazzi; Mario | Method of using relaxin as therapeutic or preventing agent |
Also Published As
Publication number | Publication date |
---|---|
KR960700742A (ko) | 1996-02-24 |
JP3269125B2 (ja) | 2002-03-25 |
EP0694307B1 (en) | 2001-08-16 |
US5709853A (en) | 1998-01-20 |
DE69427970T2 (de) | 2001-11-29 |
EP0694307A4 (en) | 1996-05-08 |
KR100278351B1 (ko) | 2001-01-15 |
DE69427970D1 (de) | 2001-09-20 |
EP0694307A1 (en) | 1996-01-31 |
JPH0648957A (ja) | 1994-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1995020395A1 (fr) | Medicament contre des maladies atopiques | |
WO1989004664A1 (en) | Methods for prevention and treatment of mucositis with granulocyte colony stimulating factor | |
EP2961426B1 (en) | Treatment of central nervous system disorders by intranasal administration of immunoglobulin g | |
EP2701728B1 (en) | Formulation comprising crh and alpha-2-macroglobulin | |
WO2023155342A1 (zh) | 一种用于防治呼吸道疾病的雾化吸入制剂及其应用 | |
US6124257A (en) | Method of treatment | |
US7468353B2 (en) | Biologically active substance of a vasoactive intestinal peptide for treating interstitial lung diseases | |
WO2003061728B1 (en) | Oral administration of interferon-tau | |
CA2365266A1 (en) | Soybean protein nutraceuticals | |
JP5231490B2 (ja) | 慢性疲労症候群の治療用の医薬の製造のための、アルファ−1−アンチトリプシンの使用 | |
US6506377B2 (en) | Interferon-alpha mediated upregulation of aquaporin expression | |
JPS60184011A (ja) | 免疫調節剤 | |
AU758832B2 (en) | Method for accelerating the rate of mucociliary clearance | |
AU1392301A (en) | Interferon gamma for the treatment of asthma | |
US6017884A (en) | Method for treating acute hepatic failure | |
EP1040190A1 (de) | Serin-proteinase-inhibitoren | |
JPH10273448A (ja) | アトピー性疾患治療のための口腔内投与用治療薬 | |
NZ201683A (en) | Pharmaceutical compositions comprising human proinsulin | |
JP2006501242A (ja) | 炎症性腸疾患の治療方法 | |
JPS631295B2 (ja) | ||
JP2002179588A (ja) | チオレドキシンファミリーに属するポリペプチド類を含む炎症予防乃至治療剤 | |
US7449177B2 (en) | Remedy for pemphigoid | |
US20230190878A1 (en) | Beta thymosin peptides for treating viral infections | |
WO1997007816A1 (en) | Solution containing igf-i | |
EP1285663B1 (en) | Protective interferon-beta against reinfection after liver transplantation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1994905228 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 08525755 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1994905228 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1994905228 Country of ref document: EP |